CRISPR Therapeutics Archives -

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical

EHA: Vertex, CRISPR build case for gene-editing drug

https://pharmaphorum.com/news/eha-vertex-crispr-build-case-for-gene-editing-drug/

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK)

CRISPR Therapeutics begins natural killer cell cancer tie-up with Nkarta

https://pharmaphorum.com/news/crispr-therapeutics-begins-natural-killer-cell-cancer-tie-up-with-nkarta/

CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to

Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal

https://pharmaphorum.com/news/nobel-winner-charpentiers-crispr-therapeutics-gets-900m-in-reworked-vertex-deal/

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

https://pharmaphorum.com/news/vertex-eyes-controllable-genetic-drugs-with-1-3bn-obsidian-alliance/

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta

ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disorders

https://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/

Data on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta

CRISPR trials yield encouraging data in blood disorders

https://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can

FDA gives go-ahead for CRISPR-based sickle cell disease trial

https://pharmaphorum.com/news/fda-gives-go-ahead-for-crispr-based-sickle-cell-disease-trial/

CRISPR Therapeutics